Investor Relations

Investing in the
Clinical Trial Automation Era.

Clinly is the digital infrastructure for the next generation of trials. We are capturing a $50B+ market by eliminating the manual translation bottleneck.

01 / THE PROBLEM

The Manual Translation
Tax is Crippling Pharma.

Phase III trials are the most expensive clinical phase, yet they rely on manual PDF-to-Database transcription.

  • 80% of trials are delayed by data collection issues.
  • $19M+ average cost for a single Phase III study.
80%

Of Trials Fail Timelines

The bottleneck: 6–10 weeks of manual data architecture setup.

Intelligent_Automation_Engine
> Analyzing Oncology Protocol PDF...
> Mapping CDISC SDTM Domains (DM, AE, LB)...
> Calculating Visit Windows (+/- 7 days)...
> Study Architecture: GENERATED (00:02:14)
02 / THE SOLUTION

Automated Readiness.

Clinly closes the "Protocol Gap" by understanding clinical context, not just text. We make trials audit-ready on Day 1, de-risking the regulatory path for sponsors.

One Week

Setup vs industry avg. 2 months

Zero Error

Manual transcription eliminated

03 / THE MARKET

The $50B Infrastructure Play.

As clinical trials move toward decentralization (DCTs) and hybrid models, the need for rapid, flexible, and automated digital architecture is exploding. Clinly is the infrastructure for the next generation of trials.

DCT

Decentralized Trials

$50B+

Total Addressable Market

AI-FIRST

Native Architecture

04 / BUSINESS MODEL

Scalability Beyond
Licensing.

We don't just sell software; we sell **Study Readiness**. Once the architecture is built, Clinly stays as the operational backbone for data capture and visit tracking.

Initial Setup Fee (Readiness)
Recurring Operational Backbone (SaaS)
Data Standardization (Upsell)

Study Lifecycle Value

PROTOCOL
ARCHITECTURE
SITE DATA CAPTURE
CDISC VALIDATION

Win the Room.

Connect with our team to explore the Clinly roadmap and the magical moment where a PDF becomes a validated clinical system.

Request Full Deck